Adverse events2,115

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 2,115

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk
other	Anaemia	Blood and lymphatic system disorders	Run-in: NIS793 + Spartalizumab + Gemcitabine/Nab-paclitaxel_On- and Post-treatment	5	11
other	Anaemia	Blood and lymphatic system disorders	Arm 1: NIS793 + Spartalizumab + Gemcitabine/Nab-paclitaxel_On- and Post-treatment	29	46
other	Anaemia	Blood and lymphatic system disorders	Arm 2: NIS793 + Gemcitabine/Nab-paclitaxel_On- and Post-treatment	33	49
other	Anaemia	Blood and lymphatic system disorders	Arm 3: Gemcitabine/Nab-paclitaxel_On- and Post-treatment	20	45
other	Anaemia	Blood and lymphatic system disorders	All Participants_On- and Post-treatment	87	151
other	Anaemia	Blood and lymphatic system disorders	Run-in: NIS793 + Spartalizumab + Gemcitabine/Nab-paclitaxel_Survival Period		0
other	Anaemia	Blood and lymphatic system disorders	Arm 1: NIS793 + Spartalizumab + Gemcitabine/Nab-paclitaxel_Survival Period		0
other	Anaemia	Blood and lymphatic system disorders	Arm 2: NIS793 + Gemcitabine/Nab-paclitaxel_Survival Period		0
other	Anaemia	Blood and lymphatic system disorders	Arm 3: Gemcitabine/Nab-paclitaxel_Survival Period		0
other	Leukocytosis	Blood and lymphatic system disorders	Run-in: NIS793 + Spartalizumab + Gemcitabine/Nab-paclitaxel_On- and Post-treatment	1	11
other	Leukocytosis	Blood and lymphatic system disorders	Arm 1: NIS793 + Spartalizumab + Gemcitabine/Nab-paclitaxel_On- and Post-treatment	3	46
other	Leukocytosis	Blood and lymphatic system disorders	Arm 2: NIS793 + Gemcitabine/Nab-paclitaxel_On- and Post-treatment	0	49
other	Leukocytosis	Blood and lymphatic system disorders	Arm 3: Gemcitabine/Nab-paclitaxel_On- and Post-treatment	2	45
other	Leukocytosis	Blood and lymphatic system disorders	All Participants_On- and Post-treatment	6	151
other	Leukocytosis	Blood and lymphatic system disorders	Run-in: NIS793 + Spartalizumab + Gemcitabine/Nab-paclitaxel_Survival Period		0
other	Leukocytosis	Blood and lymphatic system disorders	Arm 1: NIS793 + Spartalizumab + Gemcitabine/Nab-paclitaxel_Survival Period		0
other	Leukocytosis	Blood and lymphatic system disorders	Arm 2: NIS793 + Gemcitabine/Nab-paclitaxel_Survival Period		0
other	Leukocytosis	Blood and lymphatic system disorders	Arm 3: Gemcitabine/Nab-paclitaxel_Survival Period		0
other	Leukopenia	Blood and lymphatic system disorders	Run-in: NIS793 + Spartalizumab + Gemcitabine/Nab-paclitaxel_On- and Post-treatment	1	11
other	Leukopenia	Blood and lymphatic system disorders	Arm 1: NIS793 + Spartalizumab + Gemcitabine/Nab-paclitaxel_On- and Post-treatment	4	46

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04390763/events

API reference For AI assistants

Adverse events2,115

Sources 3

Read this list from software.